Cases & Investigations

Alkermes Stock Class Action Lawsuit Investigation

PRODUCT: Alkermes, plc's publicly traded securities
CASE STATUS: Under Investigation
TICKER SYMBOL: NASDAQ: ALKS
LEAD PLAINTIFF DEADLINE: February 25, 2019
CLASS PERIOD START DATE: February 17, 2017
CLASS PERIOD END DATE: November 1, 2018

Attention: Anyone who purchased Alkermes, plc’s publicly traded securities between February 17, 2017 and November 1, 2018.

Berger Montague is conducting an investigation and asking to hear from anyone who purchased or otherwise acquired Alkermes, plc’s publicly traded securities from February 17, 2017 through November 1, 2018. Alkermes may have violated federal securities law. We are interested in speaking with stock purchasers to help determine whether a class action lawsuit can be filed.

If you purchased or otherwise acquired Alkermes’ publicly traded securities between February 17, 2017 and November 1, 2018 and are interested in discussing a possible case, please contact Barbara A. Podell at 215-875-4690, Michael C. Dell’Angelo at 215-875-3080 or Phyllis M. Parker at 215-875-4647. The deadline for filing a motion for lead plaintiff in this case is February 25, 2019.

What is Alkermes, plc?

Alkermes is a global biopharmaceutical company developing medicines for the treatment of central nervous system diseases. The company has a commercial product portfolio and a clinical pipeline of product candidates for chronic diseases such as schizophrenia, depression, addiction and multiple sclerosis.

What are the allegations against Alkermes?

Alkermes and its CEO and CFO have been accused of federal securities law violations in a class action filed in the U.S. District Court for the Eastern District of New York.

The complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that:

  • (1) the FDA had advised Alkermes to follow a certain protocol in connection with its New Drug Application submission for ALKS 5461;
  • (2) Alkermes failed to follow that protocol;
  • (3) consequently, an FDA advisory committee voted 21 to 2 against the approval of ALKS 5461; and
  • (4) as a result, Alkermes’ public statements were materially false and/or misleading at all relevant times.

The complaint alleges that when the truth entered the market, investors suffered damages.

If you purchased or otherwise acquired Alkermes’ publicly traded securities from February 17, 2017 through November 1, 2018 and wish to discuss this case and/or your potential losses, please contact Barbara A. Podell at 215-875-4690, Michael C. Dell’Angelo at 215-875-3080 or Phyllis M. Parker at 215-875-4647.

Do I have to pay to consult with an attorney?

We are happy to speak with you about your potential claims free of charge. If we decide to represent you in a lawsuit, we will enter into a written contingent fee agreement with you. A contingent fee agreement means we only get paid if we win, and we will receive our fees from the amount paid by the Defendant in the case.

Lead Attorneys

Barbara Podell Headshot

Barbara A. Podell

Shareholder
Michael Dell'Angelo Headshot

Michael C. Dell'Angelo

Managing Shareholder
Phyllis Maza Parker Headshot

Phyllis Maza Parker

Shareholder

Request A Free Consultation

  • This field is for validation purposes and should be left unchanged.